Safety of IGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study

Overview

Journal Adv Ther

Date 2025 Mar 8

PMID 40056372

Authors

Hideaki Kaneto

Makiko Hatanaka

Yukiko Morimoto

Yoko Takahashi

Yasuo Terauchi

Affiliations

Soon will be listed here.

Abstract

Introduction: In this post-marketing study in Japan, the occurrence of hospital-treated hypoglycaemia and severe hyperglycaemia requiring inpatient treatment was evaluated in various cohorts of people with type 2 diabetes (T2D) newly switched to iGlarLixi, a titratable, once-daily, fixed-ratio combination of long-acting insulin glargine 100 U/mL (iGlar-100) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA, lixisenatide).

Methods: In this retrospective, observational study, acute-care hospital data from adults with T2D were analysed from the Medical Data Vision database. In Cohort 1, the incidence rate of hospital-treated hypoglycaemia following newly prescribed iGlarLixi versus iGlar-100 was assessed. Cohort 2 was subdivided to evaluate the incidence rate of hospital-treated hypoglycaemia and severe hyperglycaemia requiring inpatient treatment in people switched to iGlarLixi from either a GLP-1 RA ± oral antidiabetic drugs (OADs) or OADs alone (Cohort 2A) or from a GLP-1 RA and long-acting insulin ± OADs or long-acting insulin ± OADs (Cohort 2B).

Results: Of the 438 people in the iGlarLixi group and 9295 people in the iGlar-100 group in Cohort 1, who had a median follow-up duration of 52 and 44 days, respectively, there were zero and 0.011 (95% CI 0.006-0.018) events per person-year of hospital-treated hypoglycaemia, respectively. Cohort 2A included 201 people each in the GLP-1 RA ± OADs and OADs alone groups, with a median follow-up duration of 76 and 101 days, respectively, and Cohort 2B included 255 people in the GLP-1 RA and long-acting insulin ± OADs group and 623 people in the long-acting insulin ± OADs group, with a median follow-up duration of 73 and 62 days, respectively; no cases of hospital-treated hypoglycaemia or severe hyperglycaemia requiring inpatient treatment were observed.

Conclusion: Consistent with clinical trials, this post-marketing database study observed that newly prescribed iGlarLixi has a low risk of serious hypoglycaemia or hyperglycaemia in Japanese people with T2D, irrespective of prior antidiabetic drug treatment.

References

Holman R, Paul S, Bethel M, Matthews D, Neil H . 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15):1577-89. DOI: 10.1056/NEJMoa0806470. View

Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H . Japanese Clinical Practice Guideline for Diabetes 2019. J Diabetes Investig. 2020; 11(4):1020-1076. PMC: 7378414. DOI: 10.1111/jdi.13306. View

Blonde L, Anderson J, Chava P, Dendy J . Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. Curr Med Res Opin. 2018; 35(5):793-804. DOI: 10.1080/03007995.2018.1541790. View

Kaneto H, Takami A, Spranger R, Amano A, Watanabe D, Niemoeller E . Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical.... Diabetes Obes Metab. 2020; 22 Suppl 4:3-13. DOI: 10.1111/dom.14005. View

Terauchi Y, Nakama T, Spranger R, Amano A, Inoue T, Niemoeller E . Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study:.... Diabetes Obes Metab. 2020; 22 Suppl 4:14-23. DOI: 10.1111/dom.14036. View

Watada H, Takami A, Spranger R, Amano A, Hashimoto Y, Niemoeller E . Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial. Diabetes Care. 2020; 43(6):1249-1257. PMC: 7245357. DOI: 10.2337/dc19-2452. View

Matsuhisa M, Miyoshi H, Yabe D, Takahashi Y, Morimoto Y, Terauchi Y . Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study. Diabetes Ther. 2022; 14(1):219-236. PMC: 9880089. DOI: 10.1007/s13300-022-01333-w. View

Mizuno S, Minatoya M, Osaga S, Chin R, Imori M . Investigation of Severe Hypoglycemia Risk Among Patients with Diabetes Treated with Ultra-Rapid Lispro in Japan. Adv Ther. 2024; 42(1):413-426. PMC: 11782313. DOI: 10.1007/s12325-024-03050-1. View

Miyoshi H, Matsuhisa M, Yabe D, Takahashi Y, Morimoto Y, Terauchi Y . Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study. Diabetes Ther. 2023; 14(4):671-689. PMC: 10064399. DOI: 10.1007/s13300-023-01373-w. View

10.

Hirose T, Odawara M, Matsuhisa M, Koshida R, Senda M, Tanaka Y . Risk of hypoglycemia in Japanese people with type 2 diabetes mellitus who initiated or switched to insulin glargine 300 U/mL: A subgroup analysis of 12-month post-marketing surveillance study (X-STAR study). Diabetes Res Clin Pract. 2020; 172:108647. DOI: 10.1016/j.diabres.2020.108647. View

11.

Odawara M, Matsuhisa M, Hirose T, Koshida R, Senda M, Tanaka Y . Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study). Expert Opin Pharmacother. 2020; 21(14):1771-1780. DOI: 10.1080/14656566.2020.1785430. View